Myxothiazol

Myxothiazol
IUPAC name 7-{2'-[(1S,2E,4E)-1,6-dimethyl-2,4-heptadienyl] [2,4'-bithiazol]-4-yl}-3,5-dimethoxy-4-methyl- (2E,4R,5S,6E)-2,6-heptadienamide
Identifiers
CAS number	76706-55-3
PubChem	6437357
MeSH	Myxothiazol
Properties
Molecular formula	C25H33N3O3S2
Molar mass	487.68 g/mol
Y (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Myxothiazol (produced by the myxobacterium Myxococcus fulvus) is an inhibitor of the mitochondrial cytochrome bc1 complex (coenzyme Q - cytochrome c reductase).

Myxothiazol is a competitive inhibitor of ubiquinol, and binds at the quinol oxidation (Qo) site of the bc1 complex, blocking electron transfer to the Rieske iron-sulfur protein. Binding of myxothiazol induces a red-shift to the visible absorption spectrum of reduced haem bl. In contrast to stigmatellin, myxothiazol does not form a hydrogen bond to the Rieske iron-sulfur protein, binding instead in the 'b-proximal' region of the cytochrome b Qo site. Movement of the cytoplasmic domain of the Rieske protein is therefore unaffected by the binding of this inhibitor.